Patents by Inventor Bryant G. Darnay

Bryant G. Darnay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of osteolytic lesions by SRC kinase inhibitors
    Patent number: 7468379
    Abstract: The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bone cancer, hypercalcemia, osteolytic lesions with orthopedic implants, Paget's disease, and bone loss associated with hyperparathyroidism. Representative cancers include, but are not limited to breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, heck and neck cancers, and cervical carcinoma. Arthritic conditions include, but are not limited to adjuvant-, collagen-, bacterial- and antigen-induced arthritis, particularly rheumatoid arthritis.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: December 23, 2008
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Bryant G. Darnay, Janet E. Price, Ann Poblenz, Moshe Talpaz
  • Inhibitors of receptor activator of NF-?B and uses thereof
    Patent number: 6998383
    Abstract: The present invention provides a RANK (receptor activator of NF-?B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: February 14, 2006
    Assignee: Research Development Corporation
    Inventors: Bharat Aggarwal, Bryant G. Darnay, Sujay Singh
  • Inhibitors of receptor activator of NF-kappaB and uses thereof
    Publication number: 20040167072
    Abstract: The present invention provides a RANK (receptor activator of NF-&kgr;B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The decoy peptide inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 26, 2004
    Inventors: Bharat B. Aggarwal, Bryant G. Darnay, Sujay Singh
  • Methods and compositions using polynucleotides and polypeptides of rank-associated inhibitor (rain)
    Publication number: 20040086848
    Abstract: The present invention concerns the use of methods to treat bone loss by inhibiting osteoclast precursor cell fusion. Describe herein is the molecular cloning of a polypeptide encoding a protein termed RAIN. The functions of RAIN include regulating osteoclast differentiation and fusion events. In certain embodiments, compositions comprising polynucleotide and/or polypeptides of RAIN may be used in therapeutic compositions and methods for treating bone loss. In various embodiments, bone loss may be treated by inhibiting the differentiation of osteoclast. Inhibition of osteoclast differentiation may be accomplished by inhibiting osteoclast precursor cell fusion, thus inhibiting the formation of a multi-nucleate resorptive osteoclast.
    Type: Application
    Filed: July 29, 2003
    Publication date: May 6, 2004
    Applicant: Board of Regents, The University of Texas System
    Inventor: Bryant G. Darnay
  • Inhibitors of receptor activator of NF-kappaB and uses thereof
    Publication number: 20030013170
    Abstract: The present invention provides a RANK (receptor activator of NF-&kgr;B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
    Type: Application
    Filed: May 10, 2002
    Publication date: January 16, 2003
    Inventors: Bharat Aggarwal, Bryant G. Darnay, Sujay Singh
  • Tumor necrosis factor receptor-I-associated protein kinase and methods for its use
    Patent number: 5856161
    Abstract: The present invention provides an isolated and purified protein that associates with the cytoplasmic domain of the p60 form of the tumor necrosis factor receptor, having a molecular weight of about 52-55 kDa on SDS-PAGE, is a phosphoprotein, and does not bind to the p80 form of the tumor necrosis factor receptor. Also provided is an isolated and purified protein kinase that binds to the cytoplasmic domain of the p60 form of the tumor necrosis factor receptor, said kinase phosphorylates the p60 form of the tumor necrosis factor receptor. Also provided are various methods of manipulating this tumor necrosis factor receptor-associated protein and kinase in order to reduce various biological effects of tumor necrosis factor.
    Type: Grant
    Filed: January 3, 1996
    Date of Patent: January 5, 1999
    Assignee: Research Development Foundation
    Inventors: Bharat B. Aggarwal, Bryant G. Darnay
  • Tumor necrosis factor receptor-II-associated protein kinase and methods for its use
    Patent number: 5837817
    Abstract: The present invention provides an isolated and purified protein that associates with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor, having a molecular weight of 59 kDa on SDS-PAGE, is a phosphoprotein, and does not bind to the p60 form of the tumor necrosis factor receptor. Also provided is an isolated and purified protein kinase that associates with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor, said kinase phosphorylates both the p80 and p60 forms of the tumor necrosis factor receptor and phosphorylates a 59 kDa molecular weight protein associated with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor. Also provided are various methods of reducing the biological effects of tumor necrosis factor.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: November 17, 1998
    Assignee: Research Development Foundation
    Inventors: Bharat B. Aggarwal, Bryant G. Darnay